INCYTE CORPORATION Payments to Acquire Other Productive Assets
INCYTE CORPORATION (INCY) reported Payments to Acquire Other Productive Assets of $10.20 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherProductiveAssets · last filed 2026-04-28
- INCYTE CORPORATION payments to acquire other productive assets for the quarter ending 2026-03-31 was $10.20M, a 221.87% increase year-over-year.
- INCYTE CORPORATION payments to acquire other productive assets for the quarter ending 2025-12-31 was $21.88M, a 25.85% increase year-over-year.
- INCYTE CORPORATION payments to acquire other productive assets for the quarter ending 2025-09-30 was $14.75M, a 184.31% increase year-over-year.
- INCYTE CORPORATION payments to acquire other productive assets for the quarter ending 2025-06-30 was $19.07M, a 64.77% decline year-over-year.
- INCYTE CORPORATION payments to acquire other productive assets for fiscal 2025 was $58.87M, a 31.76% decline from fiscal 2024.
- INCYTE CORPORATION payments to acquire other productive assets for fiscal 2024 was $86.26M, a 165.54% increase from fiscal 2023.
- INCYTE CORPORATION payments to acquire other productive assets for fiscal 2023 was $32.49M, a 58.26% decline from fiscal 2022.
- INCYTE CORPORATION payments to acquire other productive assets for fiscal 2022 was $77.83M, a 57.00% decline from fiscal 2021.
| Period end | Payments to Acquire Other Productive Assets 3 month | Payments to Acquire Other Productive Assets 6 month | Payments to Acquire Other Productive Assets 9 month | Payments to Acquire Other Productive Assets 12 month |
|---|---|---|---|---|
| 2026-03-31 | $10.20M 10-Q · filed 2026-04-28 | $32.08M derived: sum of 2 quarters · filed 2026-04-28 | $46.82M derived: sum of 3 quarters · filed 2026-04-28 | $65.90M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $21.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $36.62M derived: sum of 2 quarters · filed 2026-02-10 | $55.70M derived: sum of 3 quarters · filed 2026-02-10 | $58.87M 10-K · filed 2026-02-10 |
| 2025-09-30 | $14.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $33.82M derived: sum of 2 quarters · filed 2025-10-28 | $36.99M 10-Q · filed 2025-10-28 | $54.37M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $19.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $22.24M 10-Q · filed 2025-07-29 | $39.63M derived: sum of 3 quarters · filed 2026-04-28 | $44.81M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $3.17M 10-Q · filed 2026-04-28 | $20.55M derived: sum of 2 quarters · filed 2026-04-28 | $25.74M derived: sum of 3 quarters · filed 2026-04-28 | $79.88M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $17.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $22.57M derived: sum of 2 quarters · filed 2026-02-10 | $76.71M derived: sum of 3 quarters · filed 2026-02-10 | $86.26M 10-K · filed 2026-02-10 |
| 2024-09-30 | $5.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $59.33M derived: sum of 2 quarters · filed 2025-10-28 | $68.88M 10-Q · filed 2025-10-28 | $71.15M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $54.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $63.69M 10-Q · filed 2025-07-29 | $65.96M derived: sum of 3 quarters · filed 2026-02-10 | $76.94M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $9.55M 10-Q · filed 2025-04-29 | $11.82M derived: sum of 2 quarters · filed 2026-02-10 | $22.79M derived: sum of 3 quarters · filed 2026-02-10 | $30.13M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $13.24M derived: sum of 2 quarters · filed 2026-02-10 | $20.58M derived: sum of 3 quarters · filed 2026-02-10 | $32.49M 10-K · filed 2026-02-10 |
| 2023-09-30 | $10.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $18.31M derived: sum of 2 quarters · filed 2024-10-29 | $30.22M 10-Q · filed 2024-10-29 | $51.49M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $7.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $19.24M 10-Q · filed 2024-07-30 | $40.52M derived: sum of 3 quarters · filed 2025-02-10 | $68.33M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $11.91M 10-Q · filed 2024-04-30 | $33.18M derived: sum of 2 quarters · filed 2025-02-10 | $60.99M derived: sum of 3 quarters · filed 2025-02-10 | $72.73M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $21.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $49.08M derived: sum of 2 quarters · filed 2025-02-10 | $60.83M derived: sum of 3 quarters · filed 2025-02-10 | $77.83M 10-K · filed 2025-02-10 |
| 2022-09-30 | $27.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $39.55M derived: sum of 2 quarters · filed 2023-10-31 | $56.56M 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $11.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $28.75M 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | $17.01M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $181.01M 10-K · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |